A Phase 1, Open-Label, Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VH4527079, Administered Either Intravenously or Subcutaneously to Healthy Adults and Persons With HIV
Latest Information Update: 10 Mar 2026
At a glance
- Drugs VH 4527079 (Primary) ; VH 4527079 (Primary)
- Indications HIV infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors ViiV Healthcare
Most Recent Events
- 06 Mar 2026 Status changed from recruiting to active, no longer recruiting.
- 06 Mar 2026 Planned End Date changed from 3 Feb 2027 to 9 Sep 2026.
- 06 Mar 2026 Planned primary completion date changed from 1 Feb 2027 to 9 Sep 2026.